In patients with hematological malignancies, the hematopoietic origin of DC may explain relative skewing of the T cell response towards hematopoietic cells, and targeting of hematopoiesis restricted MiHA can result in GVT reactivity in the absence of GVHD [9], [10]. The gene discussed is XIAP; the disease is graft versus host disease.